BioAtla Inc - BCAB Company Short-Term Debt

BioAtla Corp (BCAB) - corporate logo

BioAtla, Inc. (BCAB) is implementing environmental standards in drug development to minimize ecological impact. The development of "smart" antibodies ensures targeted strikes on tumors, thereby reducing side effects. However, relying on a single platform without current revenue increases financial risks. The 0.00 mark indicates the current state of liabilities, which is clearly illustrated by the short-term debt chart.

BCAB (BioAtla, Inc.) Company Short-Term Debts history from 07/04/2022 to 09/06/2026

BioAtla Inc - analytical breakdowns and key metrics (BCAB)

- price and consensus price forecast:
Stock Price BioAtla Corp|BCAB - Average Forecast Price
- market capitalization data:
Market Value BioAtla, Inc.|BCAB - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share BioAtla|BCAB - Book Capitalization|Market Value to Book Value Ratio bioatla.com|BCAB - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio BioAtla, Inc.|BCAB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity BioAtla Corp|BCAB - Company Cumulative Debt|Debt to Book Capitalization Ratio BioAtla, Inc.|BCAB - Company Long-Term Indebtedness|Company Short-Term Debts BioAtla
Fundamental company valuation:BioAtla, Inc.
Signature product of BioAtla Corp

The development of BioAtla, Inc. (BCAB) depends on successful antibody trials and interest from pharma behemoths, which requires significant operational capital. An analysis of the organization's short-term debt, measuring obligations maturing within one year, allows for an assessment of current liquidity and the pace of borrowing between reports, where a reduction in the debt load minimizes refinancing risks but may limit the pace of technological progress.

Competitors of BioAtla, Inc. (BCAB)

INCY (Incyte) - Company Short-Term Debts|HCM: Short-Term Debt|Company Short-Term Debt Nuvation Pharma NUVB|Day One Biopharmaceuticals Inc (DAWN) - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts INBX|Company Short-Term Debt I-Mab (IMAB)|Company Short-Term Debt Fennec Pharma FENC|Company Current Liabilities Heron Therapeutics, Inc.|Nuvectis Pharma, Inc - Company Short-Term Loans and Borrowings|CHRS (Coherus BioSciences, Inc.) - Company Short-Term Debt|CRBP: Short-Term Debt|Company Short-Term Debt cardiffoncology.com|BeyondSpring, Inc. (BYSI) - Company Short-Term Indebtedness|Company Short-Term Debts LIXT|Company Current Liabilities CTXR|Cellectar Biosciences - Company Short-Term Debt|Short-Term Debt BLRX (biolinerx.com)|Company Short-Term Debt Can-Fite BioPharma Ltd. CANF|Aprea Therapeutics Inc. - Company Short-Term Debt|KZIA (Kazia) - Company Short-Term Debt|SLXN - Short-Term Debt|Company Short-Term Debts NCNA (nucana.com)|Short-Term Indebtedness chimerix.com|Company Current Liabilities CYCC (Cyclacel)|Short-Term Debt G1 Pharma (GTHX)|Kronos Bio Corp (KRON) - Company Current Liabilities|Company Short-Term Loans and Borrowings Kintara Pharma KTRA|Company Current Liabilities Oncternal Therapeutics (ONCT)|Amount of Current Liabilities portagebiotech.com PRTG